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The c-Fes protein-tyrosine kinase modulates cellular
signaling pathways governing differentiation, the
innate immune response, and vasculogenesis.
Here, we report the identification of types I and II
kinase inhibitors with potent activity against c-Fes
both in vitro and in cell-based assays. One of the
most potent inhibitors is the previously described
anaplastic lymphoma kinase inhibitor TAE684. The
crystal structure of TAE684 in complex with the
c-Fes SH2-kinase domain showed excellent shape
complementarity with the ATP-binding pocket and
a key role for the gatekeeper methionine in the
inhibitory mechanism. TAE684 and two pyrazolopyr-
imidines with nanomolar potency against c-Fes
in vitro were used to establish a role for this kinase
in osteoclastogenesis, illustrating the value of
these inhibitors as tool compounds to probe the
diverse biological functions associated with this
unique kinase.
INTRODUCTION
The c-fes/fps proto-oncogene encodes a 93 kDa protein-tyro-
sine kinase (c-Fes), and together with the homologous kinase
Fer, it defines a structurally unique kinase family (reviewed in
Greer et al., 2011; Hellwig and Smithgall, 2012). Sequences of
c-fes and fps were first isolated as part of oncogenic Gag-Fes/
Fps chimeras found in several avian and feline retroviruses
(Snyder and Theilen, 1969; Wang et al., 1981), leading to subse-
quent identification of the corresponding mammalian and avian
cellular proto-oncogenes (Huang et al., 1985; Roebroek et al.,
1985). Human c-fes, which maps to chromosome 15, is ex-
pressed in embryonic tissues derived from all three germ layers
(Care` et al., 1994). In adults, c-Fes is present in a variety of cellChemistry & Biology 19,lineages, including myeloid hematopoietic, vascular endothelial,
neuronal, and epithelial cells (Care` et al., 1994; Delfino et al.,
2006; Haigh et al., 1996).
The structural organization of c-Fes is distinct from other
nonreceptor tyrosine kinases, such as c-Src and c-Abl (Greer
et al., 2011; Hellwig and Smithgall, 2012). The unique N-terminal
region features a Fes/CIP4 homology (FCH) domain, followed by
two coiled-coil motifs, a central Src-homology 2 (SH2) domain
and a C-terminal kinase domain. The FCH region and first
coiled-coil motif comprise an F-BAR homology domain. Other
F-BAR domain proteins have been implicated in the regulation
of plasma membrane curvature through phosphoinositide
binding and induction of membrane tubulation (Itoh and De
Camilli, 2006). A recent study demonstrated the ability of the
c-Fes F-BAR domain to bind phospholipids and induce
membrane tubulation in vitro, suggesting that phosphoinositides
may recruit c-Fes to cellular membranes and contribute to its
activation by FcεRI/Lyn complexes in mast cells (McPherson
et al., 2009).
c-Fes biological activity is tightly regulated in cells, with the
kinase domain adopting a catalytically repressed state (Greer
et al., 1988). Downregulation of kinase activity is maintained
despite the absence of negative regulatory structural elements,
such as an SH3 domain or a negative regulatory tail found in
the Src-family of nonreceptor tyrosine kinases (Engen et al.,
2008). Cellular c-Fes kinase activity is stimulated by the
experimental addition of the amino-terminal myristylation signal
from c-Src (Greer et al., 1994), replacement of residues of
the c-Fes kinase domain with homologous v-Fps sequences
(Kim and Feldman, 2002), introduction of a point mutation
predicted to disrupt the structure of the first N-terminal
coiled-coil domain (Cheng et al., 2001; Shaffer et al., 2009),
or substitution of the SH2 domain with that of v-Src (Rogers
et al., 2000). Interestingly, insertional mutagenesis of the
v-Fps SH2 domain reduced kinase and transforming functions,
providing some of the first evidence that the SH2 domain is
a positive regulator of kinase activity (Sadowski et al., 1986).
Subsequent studies indicated that the same is true for c-Fes
(Hjermstad et al., 1993).529–540, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 529
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c-Fes Inhibitor DiscoveryA recent crystal structure of a truncated form of c-Fes, consist-
ing of the SH2 and kinase domains, revealed the molecular
mechanisms behind the positive impact of the SH2 domain on
kinase activity (Filippakopoulos et al., 2008). Packing and
electrostatic interactions between the SH2 and the kinase
domain stabilize an active conformation of the critical aC helix
found in the kinase domain N-lobe. Crystallization with a
synthetic substrate peptide established that substrate binding
to the phosphotyrosine site of the SH2 domain stabilizes an
ordered SH2 conformation and primes the kinase for catalysis
through proper orientation of the aC helix. These structures
suggested a model of coordinated c-Fes activation in which
substrate binding to SH2 and subsequent autophosphorylation
of the activation loop on Y713 stabilize a catalytically competent
kinase domain conformation.
Several lines of evidence suggest a possible role for c-Fes
in oncogenesis. Kinase-active mutants of c-Fes drive focus-
forming activity and soft agar colony formation in rodent fibro-
blast transformation assays (Cheng et al., 2001; Li and Smithgall,
1998). More recently, c-Fes was identified as a phosphorylation
target of the constitutively active D816V mutant of c-Kit, a
mutation commonly found in human malignancies (Voisset
et al., 2007). siRNA targeting of endogenous c-Fes in TF-1 cells
expressing c-Kit D816V significantly reduced proliferation and
phosphorylation of STATs and p70 S6 kinase. Active c-Fes has
been observed in acute myeloid leukemia (AML), and reduction
of c-fes expression by RNAi demonstrated a requirement for
c-Fes in AML cell survival (Voisset et al., 2010). Downregulation
of c-Fes by siRNA treatment was also shown to reduce prolifera-
tion of two human renal carcinoma cell lines (Kanda et al., 2009).
Angiogenesis is a common hallmark of tumorigenesis (Hana-
han and Weinberg, 2000). A role for c-Fes in angiogenesis was
first suggested by the observation that membrane-targeted
c-fes expression led to hypervascularization and hemangioma
formation in transgenic mice (Greer et al., 1994). Subsequently,
c-Fes kinase activity was shown to contribute to FGF-2-induced
chemotactic cell migration and tube formation by brain capillary
endothelial cells (Kanda et al., 2000). Further studies confirmed
that c-Fes is a common mediator of PI3-kinase activation by
numerous angiogenic factors, including VEGF-A, Ang1, and
Ang2 (Kanda et al., 2007).
Delineating a role for c-Fes in cancer is complicated by obser-
vations that c-Fes may also fulfill the role of a tumor suppressor.
Large-scale sequencing of the tyrosine kinome in multiple
colorectal tumor cell lines identified c-fes as one of only a small
number of consistently mutated genes (Bardelli et al., 2003).
Subsequent work showed that none of the reported mutations
stimulated c-Fes kinase activity, and several impaired kinase
function, consistent with a tumor-suppressor role (Delfino
et al., 2006; Sangrar et al., 2005). Expression of c-Fes is readily
detected in normal colonic epithelium but is frequently absent
in matched tumor samples, as well as in human colorectal
cancer cell lines, as a result of extensive promoter methylation
(Delfino et al., 2006; Shaffer and Smithgall, 2009). In a mouse
model of breast cancer, tumor onset was accelerated in homo-
zygous null c-fes mice, and this effect was rescued by a c-fes
transgene (Sangrar et al., 2005). Taken together, these data point
to a tumor suppressor function for c-Fes in some epithelial
cancers.530 Chemistry & Biology 19, 529–540, April 20, 2012 ª2012 ElsevierSpearheaded by the clinical success of the Bcr-Abl inhibitor
imatinib in chronic myelogenous leukemia, kinases have
become the focus of major drug discovery efforts as targets
for anticancer drug therapy (Zhang et al., 2009). As summarized
previously, mounting evidence points toward a role for c-Fes in
human cancer through its involvement in cell proliferation,
survival signaling, and angiogenesis, making it an attractive
candidate for drug targeting (Kanda andMiyata, 2011). Selective
small-molecule inhibitors are urgently needed to clarify the role
of c-Fes as a dominant oncogene versus tumor suppressor,
depending upon the cellular context. Despite the intriguing
biology associated with c-Fes, no inhibitors with a useful level
of selectivity and cellular activity have been reported to date.
In this study, we report the discovery and characterization of
potent c-Fes tyrosine kinase inhibitors with cellular activity.
Using a recombinant c-Fes protein consisting of the SH2 and
kinase domains, we first screened a kinase-biased small-mole-
cule library using an in vitro kinase assay. ‘‘Hit’’ compounds
were then tested for their ability to inhibit c-Fes autophosphory-
lation andmicrotubule association in COS-7 cells and their effect
on rodent fibroblast transformation driven by constitutively
active c-Fes mutants. Using these screens, we identified both
type I and type II c-Fes kinase inhibitors from diverse chemical
classes, including diaminopyrimidines, pyrazolopyrimidines,
pyrrolopyridines, and pyrazines, with activity against c-Fes
both in vitro and in vivo. Type I inhibitors bind to the ATP-binding
site with the kinase assuming an ‘‘active’’ conformation defined
by the ‘‘DFG-motif’’ of the activation loop adopting an ‘‘in’’
conformation conducive to substrate binding. Type II inhibitors
bind to the ‘‘inactive’’ conformation with the ‘‘DFG-motif’’ in an
‘‘out’’ conformation blocking access to the substrate binding
site (Liu and Gray, 2006).
Surprisingly, we discovered that TAE684, a compound
previously identified as a potent and selective inhibitor of the
anaplastic lymphoma kinase (Alk; Galkin et al., 2007), is also
a potent inhibitor of c-Fes both in vitro and in vivo. We were
able to obtain a crystal structure of the c-Fes SH2- kinase region
in complex with TAE684, which will guide further modifications
to enhance potency and selectivity. Finally, using several of
these inhibitors as chemical probes, we were able to define
a role for endogenous c-Fes activity in osteoclast differentiation
from macrophages. Our findings represent an important first
step toward the development of potent and selective inhibitors
of c-Fes, which will have utility in the elucidation of the roles
of this enigmatic kinase in normal cellular physiology and
tumorigenesis.
RESULTS AND DISCUSSION
Identification of c-Fes Inhibitors by FRET-Based
Chemical Library Screening
The Z’-Lyte fluorescence resonance energy transfer (FRET)-
based assay platform for a high-throughput assessment of
kinase activity has been successfully used in a chemical library
screen to identify inhibitors of HIV Nef-induced Hck tyrosine
kinase activity (Emert-Sedlak et al., 2009; Rodems et al.,
2002). Here, we used this assay and a recombinant catalytically
active fragment of c-Fes, consisting of the SH2 and kinase
domains (SH2-KD) for which the crystal structure is knownLtd All rights reserved
Table 1. IC50 Values of c-Fes Inhibitors Determined In Vitro Using
a Recombinant SH2-Kinase Protein and the Z’-Lyte Assays
Compound Type (Predicted) IC50 (nM)
Diaminopyrimidines
TAE684 I 118
Triaminopyrimidines
XMD5-130 I 308
XMD6-3 I 275
HG-5-91-01 I 275
HG-5-145-01 I 537
HG-5-150-01 I 252
HG-5-56-01 I 654
Pyrazolopyrimidines
WZ-4-49-1 I 214
WZ-4-49-8 I 67
WZ-4-49-9 I 302
WZ-4-49-10 I 146
Diaminopurines
WZ-4-24-1 I 168
WZ-4-24-2 I 365
WZ-4-24-3 I 363
WZ-4-24-7 I 149
Thiazolepyridines
HG-7-127-01 II 222
Pyrrolopyridines
HG-7-92-01 II 298
Pyrazines
HG-7-27-01 II 224
Pyrimidine carbamates
WH-4-199-1 II 256
WH-4-199-2 II 422
WH-4-124-2 II 535
Concentration response curves were generated using the recombinant
c-Fes SH2-kinase protein and the Z’-Lyte assay as described under
Experimental Procedures. Compounds are organized by chemical
scaffold and predicted mode of inhibition (type I versus type II).
See also Figure S2.
Figure 1. Inhibition of Recombinant c-Fes SH2-KD Using an In Vitro
Kinase Assay and FRET-Peptide Substrate
The assay was performed as described under Experimental Procedures using
the substrate peptide Tyr2. Concentration-response curves for selected
inhibitors of different chemical classes and the structure of these compounds
are shown.
See also Figure S1 and Table S1.
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c-Fes Inhibitor Discovery(Filippakopoulos et al., 2008), to screen a kinase-biased library
of small molecules. A total of 586 compounds were initially
screened for inhibition of SH2-KD at a concentration of 1 mM
(Figure S1 available online). We found that 19 compounds
inhibited Fes SH2-KD kinase activity by 90% or more, whereas
an additional 13 compounds inhibited kinase activity by 80%–
90%. Of the inhibitors identified in the primary screen, 21
compounds representing eight diverse chemical scaffolds
were chosen for further analysis. The inhibitory activities of these
compounds were verified in dose-response experiments, and
IC50 values were determined by curve fitting (Figure S2). The
IC50 values for all 21 compounds were in the submicromolar
range (Table 1), with the lowest values observed for the pyrazo-
lopyrimidine WZ-4-49-8 (IC50 67 nM) and the diaminopyrimidine
TAE684 (IC50 118 nM). In addition to these type I inhibitors,
two putative type II inhibitors, HG-7-27-01 (IC50 224 nM)Chemistry & Biology 19,and HG-7-92-01 (IC50 292 nM), were also discovered in this
compound set. Structures and concentration-response curves
for these four inhibitors are presented in Figure 1. Chemical
syntheses and characterization data for these four compounds
are presented in the Supplemental Experimental Procedures.
Kinome-wide Selectivity of Lead Compounds
The kinome-wide selectivity for each of the four lead compounds
was assessed using KINOMEscan screening technology, a high-
throughput method for screening kinase inhibitors against
a panel of either 353 kinases (for TAE684 and HG-7-92-01) or
442 kinases (for WZ-4-49-8 and HG-7-27-01). A kinome interac-
tion map was constructed from the resulting data for each
compound (Figure S3A). This approach revealed that the diami-
nopyrimidine TAE684, a type I kinase inhibitor, possessed529–540, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 531
Figure 2. X-Ray Crystal Structure of the c-Fes SH2-Kinase Region
Bound to the Diaminopyrimidine Inhibitor, TAE684
(A) 2Fc-Fo map of TAE684 bound to the c-Fes active site. The map was
contoured at 2s.
(B) Binding mode of TAE864 in the c-Fes cocrystal structure is stabilized by
hydrogen bonds with the hinge backbone V639 and the active site K590.
(C) Detailed view of the TAE684 c-Fes interaction.
See also Figure S4 and Table S2.
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c-Fes Inhibitor Discoverya broad selectivity profile with a selectivity score of 0.38
(Karaman et al., 2008). In contrast, the pyrazolopyrimidine type
I inhibitor WZ-4-49-8, which possesses an ortho-ethoxy group,532 Chemistry & Biology 19, 529–540, April 20, 2012 ª2012 Elsevierdisplayed an exceptional selectivity profile with a selectivity
score of only 0.027. The two type II inhibitors HG-7-92-01 and
HG-7-27-01 displayed intermediate selectivity profiles (0.18
and 0.16, respectively). Selectivity profiling was intentionally
performed at relatively high inhibitor concentrations (10 mM) to
identify the full spectrum of possible targets. A complete listing
of all of the kinases profiled in the screen and the relative selec-
tivity profiles of each compound are shown in Table S1. Though
this approach provides a broadmeasure of kinase selectivity, it is
important to note that it does not necessarily translate to inhibi-
tion of kinase activity in biochemical or cellular assays. For
example, TAE684 and WZ-4-49-8 scored as strongly active for
Erk2 in the KINOMEscan assay (displacement scores of 0.3
and 0.7, respectively; Table S1). However, neither compound
showed notable inhibition of Erk2 activity in kinase assays,
with IC50 values for Erk2 inhibition at least 100-fold higher than
those observed for the inhibition of Fes (Figures S3B and S3C).
Further experiments will be required to determine whether any
other kinases identified in this in vitro displacement assay repre-
sent true alternative targets in cells, especially at concentrations
in which c-Fes is inhibited.
Three-Dimensional Structure of the c-Fes SH2-KD
Region in Complex with TAE684
The c-Fes SH2-kinase protein used in the primary screen was
crystallized in complex with TAE684, and the resulting X-ray
crystal structure was refined to 1.84 A˚ (data collection and
refinement statistics are listed under Table S2). In the crystal
structure, the regulatory aC helix assumed an active conforma-
tion as indicated by the canonical salt bridge between the
conserved aC glutamate (E607) and the active-site lysine
(K590). However, the activation segment was largely unstruc-
tured as expected for unphosphorylated, inactive c-Fes in the
absence of SH2 ligands (Filippakopoulos et al., 2008). The inhib-
itor was very well defined by electron density (Figure 2A) and
showed good shape complementarity with the c-Fes ATP
binding pocket. The inhibitor pyrimidine and aniline amines
formed two hydrogen bonds with the hinge backbone of V639
(Figure 2B). In addition, the 5-chloro substituent of TAE684
packed against the gatekeeper methionine (M636), an interac-
tion that was also observed between the related inhibitor WZ-
4002 and the T790M gatekeeper mutant of the EGF receptor
tyrosine kinase (Zhou et al., 2009). Binding was further stabilized
by hydrophobic interactions with residues A588, L638, V620,
L690, V575, and I567 (Figure 2C). The piperazine moiety of
TAE684 extended over helix aD and was shielded from the
solvent channel by a symmetry-related protein molecule.
Superimposition of the c-Fes/TAE684 cocrystal structure
with that of Alk (Bossi et al., 2010) revealed an additional polar
interaction of TAE684 with E1210, located in helix aD, which is
not present in c-Fes (Figures S4A and S4B). However, the
electron density for the piperidine-piperazine group was not
well defined in the Alk complex, suggesting that this moiety is
flexible. In c-Fes, the piperidine-piperazine group forms water-
mediated hydrogen bonds with residues G641 and G642,
located C-terminal to the hinge region (Figure S4C). Additional
water-mediated hydrogen bonds were also observed between
TAE684 and the active site lysine (K590), the P loop residues
F572 and N571, and D701 (Figure S4D).Ltd All rights reserved
Figure 3. Inhibitors of c-Fes Kinase Activity Block
of c-Fes-L145P Autophosphorylation and Microtu-
bule Localization In Vivo
(A) Confocal images of COS-7 cells expressing wild-type
GFP-c-Fes (Fes-WT) or the active GFP-c-Fes-L145P
mutant (Fes-L145P) stained with anti-Fes pY713-specific
antibody (Texas Red, pFes). Wild-type c-Fes shows
diffuse cytoplasmic distribution (upper panel) and kinase
activity is repressed, as evidenced by lack of pFes
immunofluorescence signal (lower panel). In contrast,
GFP-c-Fes-L145P is autophosphorylated at Y713 and
strongly localizes to microtubules. Representative images
of cells expressing GFP-c-Fes-L145P treated with the
inhibitors TAE684 and HG-7-27-01 are also shown.
(B) COS-7 cells expressing GFP-c-Fes-L145P were
treated with the kinase inhibitors shown for 20 hr and
the percentage of GFP-expressing cells that stained
positive for c-Fes pY713 was determined. Results with
cells expressing wild-type GFP-c-Fes (WT) and GFP-c-
Fes-L145P (LP) in the absence of inhibitors are also shown
(black bars; left). For each condition, all cells in a minimum
of ten 40X fields were scored, and the average of three
independent experiments is shown ± SD. Data points that
could not be determined due to cytotoxic effects of the
compound are indicated.
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c-Fes Inhibitor DiscoveryAnalysis of Inhibitors in a Cell-Based Assay for c-Fes
Autophosphorylation and Microtubule Localization
We next examined whether the inhibitors identified in vitro also
displayed activity against full-length c-Fes in a cell-based assay.
The N-terminal region of c-Fes, which is not part of the crystal
structure, contains two coiled-coil homology domains that
have been implicated in the regulation of c-Fes kinase activity
in cells (Hellwig and Smithgall, 2012). A leucine-to-proline point
mutation in the first coiled-coil domain (L145P), which has
been predicted to disrupt the coiled-coil structure, strongly acti-
vates c-Fes in vivo and results in fibroblast transformation
(Cheng et al., 2001). When a GFP fusion of this active c-Fes
mutant is expressed in COS-7 cells, autophosphorylation of
the c-Fes kinase domain activation loop on Y713 can be readily
detected by immunofluorescence, along with redistribution of
the protein to the prominent microtubule scaffold present in
this cell line (Laurent et al., 2004). Microtubule association results
from c-Fes-mediated phosphorylation of tubulin, followed by
association via the c-Fes SH2 domain. Association of active
c-Fes with microtubules is in striking contrast to the diffuse cyto-
plasmic distribution of wild-type c-Fes, which is downregulated,
despite the high-level overexpression achievable in this cell line
(Figure 3A).
Using the COS-7 expression system, we tested all 21 lead
compounds from the in vitro screen for their ability to inhibit
c-Fes autophosphorylation and association with microtubules
in vivo. COS-7 cells were transiently transfected with the GFP-
Fes-L145P fusion protein, followed by 24 hr incubation with
each compound at concentrations of 1, 3, and 10 mM. Treated
cells were fixed and immunostained for autophosphorylated
c-Fes using a pY713-specific antibody (Takashima et al.,
2003). As shown in Figure 3A, treatment with the compoundChemistry & Biology 19,TAE684 resulted in a dramatic loss of GFP-Fes localization
frommicrotubules and concomitant loss of pY713 immunostain-
ing. Additional experiments revealed that loss of autophosphor-
ylation and cellular redistribution of GFP-Fes-L145P can be
observed after as little as 1 hr of inhibitor treatment (data not
shown). This observation suggests that inhibition of c-Fes kinase
activity both reverses and prevents microtubule association.
Nine additional compounds also inhibited c-Fes-L145P auto-
phosphorylation and microtubule association in at least a
subset of cells. To quantify the effects of these inhibitors, the
percentage of cells showing loss of c-Fes-L145P pY713 immu-
nostaining was determined in three independent experiments,
and the results are shown in Figure 3B. The strongest inhibition
was observed with TAE684, with 70% (at 1 mM) to 90%
(at 10 mM) of cells showing loss of c-Fes-L145P activity and
microtubule association. These experiments identify TAE684
as a potent inhibitor of active c-Fes in a cellular context. The
pyrazolopyrimidines WZ-4-49-1 and WZ-4-49-8 also showed
strong effects in this system, with IC50 values in the low micro-
molar range. In contrast to these compounds, the predicted
Type II inhibitor HG-7-27-01 reduced c-Fes-L145P autophos-
phorylation in only 10%–15% of cells when tested at concentra-
tions below the cytotoxicity threshold, despite its apparent
potency in vitro. As described in the next section, this difference
may be due to a preference of this compound for the downregu-
lated conformation of the kinase domain.
Inhibition of Tubulin Phosphorylation by c-Fes In Vitro
In addition to a strong association withmicrotubules in vivo, puri-
fied c-Fes directly phosphorylates tubulin and catalyzes tubulin
polymerization in vitro (Laurent et al., 2004). In support of the
inhibitor-induced changes in c-Fes-L145P autophosphorylation529–540, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 533
Figure 4. Inhibition of Tubulin Phosphorylation by c-Fes, c-Fes-
L145P, and c-Fes SH2-KD In Vitro
(A) c-Fes-Flag and c-Fes-L145P-Flag were expressed in 293T cells, and
immunoprecipitates were subjected to in vitro kinase assays with [g32P]ATP
and purified tubulin as substrate in the presence of the inhibitors TAE684 or
HG-7-27-01 as indicated. Similar assays were conducted using the re-
combinant purified c-Fes SH2-kinase domain protein (SH2-KD). Reaction
products were separated by SDS-PAGE and transferred to PVDFmembranes,
followed by autoradiography (pFes, pTubulin). Equivalent levels of c-Fes
protein in each assay were verified by immunoblotting (Fes), and tubulin
substrate levels were confirmed by Coomassie staining (Tubulin).
(B) Concentration-response curves for TAE684 (left) and HG-7-27-01 (right), as
quantified from at least three tubulin phosphorylation assays performed for
each kinase. Average percent inhibition ± SEM for each inhibitor concentration
is shown.
See also Figure S3.
Table 2. IC50 Values for TAE684 and HG-7-27-01 Inhibition of
Tubulin Phosphorylation by Recombinant SH2-Kinase versus
Full-Length c-Fes-Flag or c-Fes-L145P-Flag
TAE684 HG-7-27-01
Kinase IC50 (nM) 95% CI (nM) IC50 (nM) 95% CI (nM)
SH2-KD 45.8 41.3–50.7 494.9 385.4–636.5
Fes-Flag 15.0 10.1–22.1 1,297 517.2–3,252
Fes-L145P-Flag 29.7 11.6–76.0 5,243 3,068–8,961
IC50 values, as well as 95% confidence intervals (CI), from three indepen-
dent determinations are shown. The concentration-response curves
used to generate these values are shown in Figure 4B.
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c-Fes Inhibitor Discoveryand microtubule localization observed in COS-7 cells, we next
performed immune-complex kinase assays using purified
recombinant tubulin as substrate. Flag-tagged wild-type or
L145P forms of c-Fes were expressed in COS-7 cells, and
immunoprecipitates were incubated with tubulin in the presence
of [g32P]ATP over a range of inhibitor concentrations. For com-
parative purposes, tubulin phosphorylation assays were also
performed with the recombinant SH2-KD form of c-Fes used in
the initial inhibitor screen. TAE648 potently inhibited tubulin534 Chemistry & Biology 19, 529–540, April 20, 2012 ª2012 Elsevierphosphorylation by both wild-type and L145P c-Fes, with
average IC50 values of 15 and 30 nM, respectively (Figure 4
and Table 2). Interestingly, the IC50 value for inhibition of full-
length wild-type c-Fes is 3-fold lower than the IC50 for the
SH2-KD protein in this assay (15 nM compared to 46 nM), sug-
gesting that TAE684 may have increased affinity for full-length
c-Fes.
For HG-7-27-01, which displayed only weak inhibition of c-
Fes-L145P autophosphorylation in COS-7 cells (Figure 3), inhibi-
tion of tubulin phosphorylation by c-Fes-L145P-Flag was also
weak in vitro, with an IC50 value of 5.2 mM (Figure 4 and Table
2). More potent inhibition was observed for wild-type c-Fes-
Flag and SH2-KD, with average IC50 values of 1.3 and 0.5 mM,
respectively. Inhibitor binding in the Type II mode typically
requires the kinase domain to be in an inactive conformation,
with the DFG-motif rotated to an outward orientation that allows
for access to a hydrophobic pocket adjacent to the ATP-binding
site (Liu and Gray, 2006). The observed differences in IC50 values
for inhibition of wild-type versus the L145P and truncated
forms of c-Fes by HG-7-27-01 suggest a bias of this compound
toward the inactive conformation of the kinase as expected for
a type II inhibitor. In addition, these results provide indirect
evidence that the unique Fes N-terminal region may influence
the conformation of the inhibitor binding site in the kinase
domain. Potent inhibition of tubulin phosphorylation by these
c-Fes kinases was also observed for WZ-4-49-8 and HG-7-92-
01, with IC50 values against wild-type c-Fes-Flag of 127 nM
and 306 nM, respectively (Figures S3B and S3C and data not
shown). No significant differences in potency against wild-type
c-Fes over the L145P mutant were observed in this assay for
these compounds. These results are consistent with the inhibi-
tion of c-Fes autophosphorylation and microtubule association
in COS cells by these compounds (Figure 3).
c-Fes Inhibitors Selectively Inhibit Rodent Fibroblasts
Transformed by Active c-Fes Mutants
but Not by the Src-family Kinase Hck
We next investigated whether the compounds that potently
inhibited c-Fes activity in vitro and in the COS cell system could
also suppress oncogenic transformation of cells by active forms
of c-Fes. In previous work, we established that Rat-2 fibroblasts
undergo rapid transformation upon stable expression of con-
stitutively active mutants of c-Fes, including the N-terminal
coiled-coil domain mutant L145P used in the COS cell assay
(Cheng et al., 2001). Using a soft agar colony-forming assay forLtd All rights reserved
Figure 5. Inhibition of Soft Agar Colony Formation by Rodent Fibro-
blasts Transfected with Transforming Variants of c-Fes
Rat-2 fibroblasts were transformed with a constitutively active c-Fes-L145P
coiled-coil mutant, a c-Fes/v-Fps chimeric kinase, a tail-activated mutant of
the Src-family kinase Hck (Hck-YF), or the active Hck mutant plus a T338M
gatekeeper mutation (Hck-TMYF). Fibroblast transformation was determined
in a soft agar colony formation assay in the presence of 0.1% DMSO (control)
and increasing concentrations of TAE684 as shown.
(A) Scanned images of representative plates showing stained soft agar
colonies.
(B) The number of transformed colonies was determined from the scanned
images using Quantity One software (Bio-Rad). Soft agar colony growth is
expressed as the mean percent of colonies observed relative to the untreated
control in triplicate assays ± SD.
(C) Transformed Rat-2 cells were grown in monolayer culture and treated with
the indicated concentrations of TAE684 for 16 hr. Cell lysates were prepared
and autophosphorylation of the transforming kinases were assessed by
immunoblotting with phosphospecific antibodies.
(D) The data shown in (C) were quantified, and IC50 values were determined
by curve fitting.
See also Figure S5.
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c-Fes Inhibitor Discoveryanchorage-independent growth, we first tested the ability of
TAE684 to inhibit Rat-2 transformation by two different active
forms of c-Fes. Rat-2 cells expressing GFP fusions of c-
Fes-L145P or an active c-Fes/v-Fps chimera (Kim et al., 2004)
were grown in soft agar in the presence of various inhibitorChemistry & Biology 19,concentrations, and the number of transformed colonies was
counted two weeks later. As shown in Figure 5, TAE684
potently inhibited soft agar colony formation by Rat-2 cells
expressing either of the transforming variants of c-Fes by
more than 50% at 100 nM. Growth of control Rat-2 cells in
monolayer culture was only slightly reduced at this concentra-
tion of TAE684, strongly supporting a direct effect of the inhib-
itor on c-Fes-mediated transformation (Figure S5). Complete
inhibition of c-Fes-mediated soft agar colony formation was
observed with TAE684 at 400 nM (c-Fes/v-Fps) and 600 nM
(c-Fes-L145P).
To rule out a role for Src-family kinases in the inhibitory effect
of TAE684 on Rat-2 fibroblast transformation, we also performed
soft agar colony assays using cells transformed by an active
mutant of the Src-family kinase Hck (Briggs and Smithgall,
1999; Lerner and Smithgall, 2002). In contrast to the strong
inhibition of c-Fes-mediated transformation by TAE684, only
minimal inhibition of Hck-mediated soft agar colony formation
was observed with 200 nM TAE684 (Figure 5). Complete loss
of soft agar colony growth was observed at 1 mM TAE684 with
both the c-Fes and Hck transformants. However, growth of
control Rat-2 cells expressing GFP alone was reduced by 50%
at 1 mM TAE684 after 72 hr and completely abolished with
a concentration of 3 mM of this compound. Together, these
results indicate that the effects of TAE684 on Hck-transformed
fibroblasts are largely due to nonspecific suppression of cell
growth as concentrations approach 1 mM or higher.
One important structural difference between the c-Fes and
c-Src kinase families is the identity of the amino acid that
occupies the ‘‘gatekeeper’’ position adjacent to the ATP binding
site in the kinase domain. This residue impacts the access of
some small-molecule inhibitors to a hydrophobic cavity that is
an important determinant of inhibitor specificity. In Hck and all
other members of the Src-kinase family, threonine occupies
the gatekeeper position, whereas a bulkier methionine residue
is present in this position in c-Fes. In the X-ray crystal structure
of the c-Fes kinase domain, the gatekeeper methionine (M636)
comes in very close contact with the chloro group of TAE684
(Figure 2). To evaluate whether this key inhibitor specificity
determinant impacts the sensitivity of Hck to TAE684, we
created an active form of Hck in which the gatekeeper threonine
was replaced by methionine. Remarkably, this single amino
acid substitution dramatically enhanced the sensitivity of Hck-
transformed fibroblasts to inhibition by TAE684 in a manner
very similar to cells transformed with the c-Fes mutants (Fig-
ure 5). These results suggest that the gatekeeper residue is a
critical specificity determinant for TAE684.
To correlate inhibition of transforming activity with effects on
kinase activity, we next treated monolayer cultures of trans-
formed Rat-2 cells with a range of TAE684 concentrations and
assayed the autophosphorylation status of each kinase by
immunoblotting the cell lysates with phosphospecific anti-
bodies against the activation loop phosphotyrosine residues
(Figures 5C and 5D). In agreement with the selectivity of
TAE684 observed in the soft agar colony assays, both c-Fes
and the Hck-TMYF gatekeeper mutant were sensitive to
TAE684 treatment (IC50 values of 88 and 685 nM, respectively),
whereas Hck-YF autophosphorylation remained largely unaf-
fected (IC50 > 10 mM).529–540, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 535
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with WZ-4-49-8 and HG-7-92-01 (Figure S5), both of which
demonstrated strong inhibition of c-Fes in vitro. WZ-4-49-8
potently inhibited c-Fes-L145P-mediated soft agar colony
growth and showed remarkable selectivity for c-Fes-L145P
over several active SFKs tested. This pyrazolopyrimidine in-
hibited c-Fes-L145P-mediated soft agar colony formation by
more than 80% at 100 nM, whereas cells transformedwith active
Hck showed no reduction in soft agar growth at this concentra-
tion. Interestingly, Rat-2 cells transformed by either of two active
SFK mutants carrying a threonine to methionine gatekeeper
mutation (Hck-TMYF and Yes-TMYF) were inhibited to 61%
and 25% of control values at 300 nM, respectively. These results
support an important role for the gatekeeper residue in deter-
mining inhibitor specificity as described previously for TAE684.
HG-7-92-01 was much less potent than the other two com-
pounds in the transformation assay, producing only 50% inhibi-
tion of c-Fes-L145P-mediated colony forming activity at 1 mM. A
similar degree of inhibition was also observed for fibroblasts
transformed with activated Hck, as well as the Hck-TM mutant,
indicating a relative lack of specificity for c-Fes in this assay.
c-Fes Inhibitors Reveal a New Role for c-Fes Kinase
Activity in Differentiation of Macrophages
to Osteoclasts
Having identified a group of structurally distinct inhibitors for
c-Fes kinase activity, we next investigated the utility of these
compounds as chemical probes for endogenous c-Fes function.
For these experiments, we turned to macrophages, one of the
cell lineages in which c-Fes is most strongly expressed. Macro-
phages in turn give rise to osteoclasts, the multinucleated cells
critical for resorption of bone (Boyle et al., 2003). This process
is regulated in part by the coordinated action of the macrophage
colony-stimulating factor (M-CSF) and RANK ligand (RANKL),
where M-CSF promotes macrophage proliferation and survival,
whereas receptor activator of nuclear factor kappa-B ligand
(RANKL) induces differentiation. Given the strong expression of
c-Fes in macrophages and its role myeloid differentiation (Craig,
2012), we were interested to see if c-Fes may contribute to
induction of the osteoclast phenotype. To test this hypothesis,
we employed both bone-marrow-derived macrophages (BMM)
and the RAW 264.7 macrophage cell line. As shown in Figure 6,
treatment of BMM with M-CSF and RANKL induced strong
induction of osteoclast differentiation, assessed as the formation
of multinucleated cells that stained positive for tartrate-resistant
acid phosphatase (TRAP). Remarkably, the c-Fes inhibitors
TAE684 and WZ-4-49-8 (as well as the WZ-4-49-8 analog WZ-
4-49-1) dramatically inhibited differentiation in this system, with
IC50 values in the submicromolar range. Very similar results
were observed using the same inhibitors in RAW 264.7 cells,
where osteoclast differentiation was driven by RANKL in combi-
nation with vascular endothelial growth factor instead of M-CSF
(Figure 6B). Importantly, none of the c-Fes inhibitors produced
toxic effects on primary macrophages or RAW 264.7 cells
when cultured in the absence of the differentiation inducers for
eight days (data not shown).
As an independent validation of a role for c-Fes in osteoclast
differentiation indicated by the inhibitors, we targeted endoge-
nous c-Fes by transient siRNA transfection of RAW 264.7 cells536 Chemistry & Biology 19, 529–540, April 20, 2012 ª2012 Elsevier(Figures S6A–S6C). Transfection with three murine c-Fes-
specific siRNAs reduced c-Fes mRNA and protein expression
by 50% (Figures S6A and S6B), a level comparable to pub-
lished targeting efficiencies by transient siRNAs in RAW264.7
cells (Wang andGrainger, 2010). Targeting of c-Fes had no effect
on themRNA levels of the closely related Fer kinase (Figure S6A).
Transfection with c-Fes-specific siRNAs suppressed RANKL-
driven formation of TRAP-positive polykaryons when compared
to mock-transfected cells and cells transfected with nonspecific
control siRNA (Figure S6C). In addition, mRNA analyses of
siRNA-transfected cells by quantitative real-time reverse tran-
scriptase-polymerase chain reaction (RT-PCR) revealed that
the knockdown of c-Fes reduced the expression of the
osteoclast marker Cathepsin K in the cytokine-stimulated cell
population, whereas basal expression levels of Cathepsin K in
unstimulated RAW 264.7 remained unchanged (Figure 6C).
This reduction in RANKL-stimulated upregulation of Cathepsin
K mRNA levels is reproduced by treatment with c-Fes inhibitor
compounds at submicromolar concentrations (Figure 6D). Taken
together, these results suggest that c-Fes activity is required
for the differentiation of osteoclasts from macrophages and
identify c-Fes as a possible therapeutic target for the treatment
of bone loss associated with cancer metastasis and aging
(Roodman, 2004).
Because the kinome-selectivity profile identified Erk kinases
as possible alternative targets for TAE684 and WZ-4-49-8, we
performed a control osteoclast differentiation assay from RAW
264.7 macrophages in the presence of the Erk inhibitor
FR180204 (Figures S6C and S6D). Treatment with 1 or 10 mM
FR180204 did not influence osteoclast differentiation, ruling
out the Erk pathway as a target for TAE684 and WZ-4-49-8.
These results are consistent with the very low potency of
TAE684 and WZ-4-49-8 toward Erk in an in vitro kinase assay
(Figure S3).
SIGNIFICANCE
Here, we describe, to our knowledge, the first inhibitor
discovery campaign directed at the c-Fes protein-tyrosine
kinase. Implicated in diverse physiological processes,
c-Fes regulates innate immune receptor signaling, myeloid
differentiation, and vasculogenesis. c-Fes has also been
implicated in tumorigenesis, where it may act as a dominant
oncogene or tumor suppressor depending upon the cellular
context. Despite the importance of c-Fes to normal cellular
function and disease, no useful inhibitors of c-Fes kinase
activity have been described. Using both in vitro and cell-
based focused library screens, we identified eight distinct
chemotypes with potent activity against c-Fes. One of the
most potent compounds is TAE684, a diaminopyrimidine
previously developed as an inhibitor of the NPM-Alk fusion
kinase associated with anaplastic lymphoma. The X-ray
crystal structure of TAE684 bound to the c-Fes SH2-kinase
region reveals the basis of inhibitor action, including a role
for the gatekeeper position in the c-Fes kinase domain.
The importance of the c-Fes gatekeeper methionine for
TAE684 binding was confirmed by replacement of the threo-
nine residue found at this position in members of the Src
kinase family. Substitution of Src family kinase gatekeeperLtd All rights reserved
Figure 6. c-Fes Inhibitors Suppress Osteoclast Differentiation from Bone Marrow-Derived Macrophages and RAW 264.7 Cells and Reduce
RANKL-Induced Upregulation of the Osteoclast Marker Cathepsin K
Mouse BMM (A) and RAW 264.7 mouse macrophages (B) were cultured with 100 ng/ml RANKL and M-CSF (BMM) or VEGF-A (RAW 264.7 cells) to induce
osteoclast formation in the presence of the indicated c-Fes inhibitors at 0.5 and 2.0 mM. Control cultures without inhibitors were supplemented with the DMSO
carrier solvent (0.1%). Cells were fixed and stained for tartrate-resistant acid phosphatase (TRAP) activity. Representative fields of DMSO and inhibitor-treated
cells are shown on the left. TRAP-positive multinuclear cells were counted from three independent cultures, and the mean values are plotted on the right ± SD.
Three independent experiments produced comparable results. All inhibitor-treated cultures exhibited significantly fewer differentiated cells relative to the
DMSO-treated control (p < 0.05 in each case). In additional experiments, RAW264.7 cells transfected with c-Fes-specific siRNAs were grown in the presence of
VEGF-A and RANKL for six days (C, left panel) or in the absence of cytokines for 24 hr (C, right panel). RNA was isolated and levels of the osteoclast marker
Cathepsin K were analyzed by real-time quantitative RT-PCR. Mean expression values ± SEM of triplicate samples are plotted relative to control cells.
Quantitative RT-PCRwas used to measure Cathepsin KmRNA expression in cell populations stimulated for six days with RANKL in the presence of DMSO or the
indicated concentrations of c-Fes inhibitors (mean ± SEM, Figure 6D).
See also Figure S6.
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c-Fes Inhibitor Discoveryresidues with methionine dramatically enhanced their
sensitivity to inhibition by TAE684 in a cell-based assay.
In addition to TAE684, several pyrazolopyrimidines also
showed remarkable potency and selectivity for c-Fes. UsingChemistry & Biology 19,these inhibitors as chemical probes, we discovered a role for
endogenous c-Fes function in osteoclast formation from
cultured macrophages, a physiological site of c-Fes ex-
pression. This observation identifies c-Fes as a possible529–540, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 537
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c-Fes Inhibitor Discoverytherapeutic target in osteoporosis as well as the osteolytic
bone disease associated with multiple myeloma. In
summary, our study supports future development of c-Fes
inhibitors with enhanced potency and specificity. Such
compounds will represent important tools for elucidating
the complex roles of c-Fes in innate immunity, differentia-
tion, and cancer etiology.
EXPERIMENTAL PROCEDURES
Chemical Library Screen
The chemical library screen for c-Fes inhibitors was performed using the
Z’-Lyte kinase assay system (Invitrogen/Life Technologies, Grand Island,
NY, USA). This FRET-based assay utilizes a synthetic substrate peptide
(Tyr2) labeled with the fluorophores coumarin and fluorescein on opposite
peptide termini (Rodems et al., 2002). In a two-step reaction process, the
substrate peptide is first incubated with the kinase to allow for phosphorylation
of a single tyrosine residue. In the second step, site-specific proteolytic
cleavage of nonphosphorylated, but not of phosphorylated, peptide occurs.
The coumarin and fluorescein fluorophores constitute a FRET-pair and peptide
cleavage results in loss of the FRET signal. Kinase activity is monitored by
measuring the emission ratio after excitation of the donor fluorophore:
Emission Ratio=
Coumarin Emissionð445 nmÞ
Fluorescein Emissionð520 nmÞ:
High kinase activity results in a low emission ratio, whereas inhibition of
kinase activity results in a high emission ratio.
Reactions were carried out in a 384-well plate format in a volume of 10 ml in
accordance with the manufacturer’s protocols. Initial titration of kinase input
verified linear reaction conditions for 25 ng of recombinant c-Fes SH2-KD
with a 1 hr reaction time at room temperature in the presence of 50 mM ATP.
The chemical library screen was performed at 1 mM final compound concen-
tration. IC50 values of ‘‘hit’’ compounds, defined as those inhibiting Fes activity
by at least 80% in the primary screen, were determined using 10-point serial
dilutions of compounds ranging from 0.5 nM to 10 mM. Results were graphed
and IC50 values determined by curve fitting using Prism (Graph Pad).
Tubulin Phosphorylation Assay
COS-7 cells (5 3 105) were seeded onto 60 mm culture dishes and grown at
37C for 24 hr. The cells were transfected with pCDNA3.1 vectors carrying
c-Fes-Flag or c-Fes-L145P-Flag and grown for an additional 20 hr. Cell
extracts were prepared by sonication in 600 ml of Fes lysis buffer (50 mM
Tris-HCl [pH 7.4], 1 mM EDTA, 50 mM NaCl, 1 mM MgCl2, 0.1% Triton
X-100, protease inhibitor cocktail [Calbiochem/EMD Millipore, Billerica, MA,
USA], 2 mM Na3VO4, and 20 mM NaF). Kinases were immunoprecipitated
using 2 mg of anti-Flag antibody (sc-807; Santa Cruz Biotechnology, Santa
Cruz, CA, USA). The immunoprecipitates were washed twice in RIPA buffer,
twice in kinase assay buffer (50 mM HEPES [pH 7.4] and 10 mM MgCl2), and
resuspended in kinase assay buffer to give a final volume of 100 mL. For reac-
tions using recombinant c-Fes SH2-KD, 25 ng of kinase were diluted in 10 ml
kinase assay buffer.
For kinase reactions, 10 ml of each immunoprecipitate was incubated with
2 mg of bovine tubulin (Cytoskeleton, Denver, CO, USA), 10 mCi of [g32P]
ATP, and inhibitor in kinase assay buffer in a total volume of 20 mL. The final
DMSO concentration in all reactions was 1%. Following incubation for
10 min at 30C, reactions were quenched by the addition of sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer and
incubation at 95C for 5 min. The reaction products were analyzed by SDS
gel electrophoresis followed by transfer to polyvinylidene fluoride (PVDF)
membranes and autoradiography. Consistent input of Fes and tubulin was
verified by western blotting and Coomassie staining of the membrane, respec-
tively. Relative tubulin phosphorylation was quantified by image analysis of
the autoradiographs using ImageJ. IC50 values were determined by plotting
phosphotubulin levels relative to the dimethyl sulfoxide (DMSO) control against
the inhibitor concentration followed by curve fitting using Prism.538 Chemistry & Biology 19, 529–540, April 20, 2012 ª2012 ElsevierCell-Based Assay for Microtubule Association
Association of active c-Fes with microtubules can be readily monitored by
expression of GFP-fusions of active c-Fes mutants in transfected COS-7 cells
(Laurent et al., 2004). To determine the effect of inhibitor compounds on c-Fes
autophosphorylation and subcellular localization, COS-7 cells were grown in
48-well plates. Inhibitors were added 24 hr later in 0.2% DMSO. Immediately
following the addition of the inhibitors, the cells were transfected with expres-
sion plasmids encoding GFP-Fes-L145P or the wild-type GFP-Fes control
using the Fugene 6 transfection reagent (Roche, Indianapolis, IN, USA). Cells
were fixed and immunostained 24 hr later with a pY713-specific antibody
(Takashima et al., 2003) and a secondary antibody conjugated to Texas Red
(Southern Biotech, Birmingham, AL, USA). Fluorescence and subcellular local-
ization were evaluated using a Nikon TE300 inverted microscope equipped
with a SPOT CCD high-resolution digital camera. For the images in Figure 3A,
COS-7 cells were grown, treated with inhibitors and subsequently fixed and
immunostained on glass coverslips. Coverslips were mounted on slides, and
images were taken using an Olympus Fluoview FV1000 confocal microscope.
Image acquisition settings were unchanged between treated and control
slides.
Rat-2 Fibroblast Transformation Assay
The construction of GFP-fusions of c-Fes-L145P and the c-Fes/v-Fps chimera
in the retroviral expression vector pSRaMSVtkneo, the production of recombi-
nant retroviruses, and the retroviral infection of Rat-2 fibroblasts are described
in detail elsewhere (Cheng et al., 2001). Stably transfected Rat-2 cells were
maintained in Dulbecco’s modified Eagle’s Medium supplemented with 10%
FBS and 400 mg/ml G418. For the soft agar colony formation assays, 35 mm
culture dishes were prepared with bottom layers of 1 ml of 0.5% Seaplaque
agarose in growthmedium. This cell-free layer also contained test compounds
at twice the final assay concentration and 0.2% DMSO. Bottom layers were
solidified at 4C. Retrovirally transduced Rat-2 cells were trypsinized to
a single-cell suspension and resuspended at a concentration of 10,000
cells/ml in medium containing 0.33% Seaplaque agarose. Each cell suspen-
sion (1 ml) was layered onto the drug-containing bottom layer and allowed
to solidify at 4C, after which the plates were incubated at 37C for 13 days.
Soft agar colonies were stained for 1 hr at 37C with thiazolyl blue tetrazolium
bromide (MTT) in growth medium (1 mg/ml; 1 ml/plate). Colony counts were
obtained from scanned images of the plates with QuantityOne software
(Bio-Rad, Hercules, CA, USA). A sensitivity setting of 5 and averaging setting
of 5 were applied to all counts. For the immunoblot analyses in Figures 5C and
5D, cells were seeded in 12-well plates at 50,000 cells/well and grown for 48 hr.
Inhibitors were added at the indicated concentrations and cells were cultured
for an additional 16 hr. Extracts were prepared using RIPA buffer containing 1X
protease inhibitors (Calbiochem), 1 mM Na3VO4, and 1 mM NaF. Anti-Fes
pY713, anti-Src pY418 (Invitrogen), anti-Hck sc-72, and anti-Fes sc-7670
(Santa Cruz) were used for immunodetection. IC50 values were determined
using Prism.
Isolation and Culture of Bone Marrow Monocytes/Macrophages
Six-week-old male ddY mice were purchased from Kyudo Co. Ltd. (Tosu,
Japan). All animal work was performed at the Nagasaki University Graduate
School of Biomedical Sciences with Institutional Animal Care and Use
Committee approval in accordance with institutional guidelines. Hematopoi-
etic cells were isolated by the perfusion of femurs and tibias with a-MEM
(Sigma-Aldrich Japan, Tokyo, Japan) containing 10% FBS (Invitrogen) and
mononuclear cells were enriched by Histopaque-1077 density gradient centri-
fugation (Sigma-Aldrich Japan). Mononuclear cells were cultured overnight in
a-MEM containing 10% FBS, and nonadherent cells were collected by centri-
fugation and seeded into 6 cm dishes in a-MEM containing 10% FBS and
20 ng/ml recombinant human M-CSF (R&D Systems, Minneapolis, MN,
USA). Seven days later, adherent cells (BMM) were harvested with trypsin
and seeded into 48-well plates for osteoclast differentiation in growth medium
containing 20 ng/ml M-CSF at a density of 2 3 104 cells/cm2.
Osteoclast Differentiation Assay
BMMs were cultured in the presence of recombinant human soluble RANK
ligand (RANKL; PeproTech, Rocky Hill, NJ, USA) and M-CSF for eight days.
RAW 264.7, obtained from the American Type Culture Collection, wereLtd All rights reserved
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(PeproTech), and 100 ng/ml RANKL. Cultures were fixed with 10% buffered
formalin, followed by an ethanol:acetone (1:1) wash. Tartrate-resistant acid
phosphatase (TRAP)-positive cells were visualized using the TRAP staining
kit (Sigma-Aldrich), and the number of TRAP-positive multinucleated cells (at
least three nuclei per cell) was counted under the microscope. For each exper-
iment, cells in three separate wells were counted and the mean osteoclast
number/well ± SD was calculated. Statistical analysis was performed using
Mann-Whitney’s U-test, and differences between samples were considered
significant when the p-value was < 0.05.Chemical Synthesis
Synthetic routes to compounds TAE684, WZ-4-49-8, HG-7-92-01, and HG-7-
27-01 are provided in the Supplemental Experimental Procedures.X-Ray Crystallography
The recombinant c-Fes SH2-kinase domain protein was expressed in
Escherichia coli and purified as described previously (Filippakopoulos et al.,
2008). Crystallization was conducted using the sitting drop vapor diffusion
method at 4C. Aliquots of the purified proteins were dispensed for crystalliza-
tion using aMosquito crystallization robot (TTP Labtech, Royston, UK). Coarse
screenswere typically set up onGreiner 3-well plates using three different drop
ratios of precipitant to protein per condition (2:1, 1:1, and 1:2; 150 nl final
volume). c-Fes crystals with TAE684 (1 mM final concentration) were grown
by mixing 100 nl of the protein (6.0 mg/ml) with a 50 nl of reservoir solution
containing 0.1 M SPG (pH 8.0) and 30% PEG 1000. Crystals were flash frozen
in liquid nitrogen. X-ray data were collected in-house on an FR-E Superbright
source using an RAXIS IV plate detector at 1.542 A˚. Indexing and integration
were carried out using MOSFLM (Leslie and Powell, 2007), and scaling was
performed with SCALA (Evans, 2007). Initial phases were calculated bymolec-
ular replacement with PHASER (McCoy et al., 2005), using the knownmodel of
c-Fes SH2-kinase (Protein Data Bank [PDB]: 3BKB; Filippakopoulos et al.,
2008). Initial models were built by ARP/wARP (Perrakis et al., 1999), and
building was completed manually with COOT (Emsley and Cowtan, 2004).
Refinement was carried out in REFMAC5 (Murshudov et al., 1997). Thermal
motions were analyzed using TLSMD (Painter and Merritt, 2006), and
hydrogen atoms were included in late refinement cycles. Crystallographic
data and refinement statistics can be found in Table S2. The crystal coordi-
nates and structure factor file will be deposited in the RCSB Protein Data
Bank prior to publication.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.chembiol.2012.01.020.ACKNOWLEDGMENTS
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